{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:36:53Z","timestamp":1792798613242,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"European Alliance of Associations for Rheumatology and Assessment of SpondyloArthritis international Society","id":[{"id":"https:\/\/ror.org\/05gp2t051","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1136\/ard-2022-223298","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T09:55:16Z","timestamp":1666346116000},"page":"130-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"title":["Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8547","authenticated-orcid":false,"given":"Casper","family":"Webers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-0939","authenticated-orcid":false,"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1954-0229","authenticated-orcid":false,"given":"Alexandre","family":"Sepriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9449-6056","authenticated-orcid":false,"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0577-6620","authenticated-orcid":false,"given":"Robert B M","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-9087","authenticated-orcid":false,"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-158X","authenticated-orcid":false,"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-3726","authenticated-orcid":false,"given":"Elena","family":"Nikiphorou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2022-223298_bib1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib5","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the International ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 update of the International ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib7","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1136\/ard.2005.041137","article-title":"ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib9","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","article-title":"Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review Informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"3","author":"Sepriano","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223298_bib10","doi-asserted-by":"crossref","first-page":"iv79","DOI":"10.1093\/rheumatology\/keaa435","article-title":"Treatment strategies in axial spondyloarthritis: what, when and how?","volume":"59","author":"Fragoulis","year":"2020","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review Informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib12","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","author":"Ramiro","year":"2022","journal-title":"Accepted for publication"},{"key":"10.1136\/ard-2022-223298_bib13","author":"Webers"},{"key":"10.1136\/ard-2022-223298_bib14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"Rob 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1136\/ard-2022-223298_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223298_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1136\/ard-2022-223298_bib17","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3899\/jrheum.170487","article-title":"Safety and efficacy of golimumab administered intravenously in adults with ankylosing spondylitis: results through week 28 of the GO-ALIVE study","volume":"45","author":"Deodhar","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3899\/jrheum.170408","article-title":"Whole-Body magnetic resonance imaging in axial spondyloarthritis: reduction of Sacroiliac, spinal, and Entheseal inflammation in a placebo-controlled trial of adalimumab","volume":"45","author":"Krabbe","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.40866","article-title":"A Fifty-Two-Week, randomized, placebo-controlled trial of Certolizumab pegol in Nonradiographic axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/art.41607","article-title":"Is treatment in patients with suspected Nonradiographic axial spondyloarthritis effective? six-month results of a placebo-controlled trial","volume":"73","author":"Rusman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib21","doi-asserted-by":"crossref","first-page":"566160","DOI":"10.3389\/fmed.2020.566160","article-title":"Head-To-Head comparison of etanercept vs. adalimumab in the treatment of ankylosing spondylitis: an open-label randomized controlled crossover clinical trial","volume":"7","author":"Wei","year":"2020","journal-title":"Front Med"},{"key":"10.1136\/ard-2022-223298_bib22","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/S2665-9913(19)30013-X","article-title":"IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial","volume":"1","author":"Li","year":"2019","journal-title":"The Lancet Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40259-020-00408-z","article-title":"Comparison of the efficacy and safety of adalimumab (Humira) and the adalimumab Biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-blind, parallel, phase III clinical trial","volume":"34","author":"Su","year":"2020","journal-title":"BioDrugs"},{"key":"10.1136\/ard-2022-223298_bib24","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40744-021-00276-1","article-title":"Safety and efficacy of prefilled liquid Etanercept-Biosimilar Yisaipu for active ankylosing spondylitis: a multi-center phase III trial","volume":"8","author":"Zhao","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223298_bib25","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223298_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, measure 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223298_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2022-223298_bib28","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase III China-centric study, measure 5","volume":"133","author":"Huang","year":"2020","journal-title":"Chin Med J"},{"key":"10.1136\/ard-2022-223298_bib29","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/rheumatology\/keab784","article-title":"Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3B trial","volume":"61","author":"Behrens","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib30","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/art.41477","article-title":"Improvement of signs and symptoms of Nonradiographic axial spondyloarthritis in patients treated with Secukinumab: primary results of a randomized, placebo-controlled phase III study","volume":"73","author":"Deodhar","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib31","doi-asserted-by":"crossref","first-page":"714.1","DOI":"10.1136\/annrheumdis-2021-eular.1033","article-title":"POS0910\u2005EVALUATION OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE MULTICENTER, RANDOMISED, DOUBLE-BLIND, PHASE IV ASTRUM-TRIAL","volume":"80","author":"Kiltz","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211051471","article-title":"Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial","volume":"13","author":"Poddubnyy","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223298_bib33","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223298_bib34","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223298_bib36","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.47360\/1995-4484-2020-376-386","article-title":"Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5\/ASTERA","volume":"58","author":"Mazurov","year":"2020","journal-title":"Rheumatology Science and Practice"},{"key":"10.1136\/ard-2022-223298_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib39","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib40","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib42","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","article-title":"Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial","volume":"80","author":"Molto","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","article-title":"Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study","volume":"392","author":"Landew\u00e9","year":"2018","journal-title":"Lancet"},{"key":"10.1136\/ard-2022-223298_bib44","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1136\/annrheumdis-2019-216839","article-title":"Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib45","doi-asserted-by":"crossref","first-page":"70.1","DOI":"10.1136\/annrheumdis-2020-eular.1322","article-title":"OP0107\u2005Etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of re-embark, an open-label, phase IV trial","volume":"79","author":"Van den Bosch","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib46","doi-asserted-by":"crossref","first-page":"80.1","DOI":"10.1136\/annrheumdis-2021-eular.1354","article-title":"OP0138\u2005FEASIBILITY OF PROGRESSIVE ANTI-TNF TAPERING IN AXIAL SPONDYLOARTHRITIS PATIENTS IN LOW DISEASE ACTIVITY: RESULTS FROM THE MULTICENTER NON-INFERIORITY PROSPECTIVE RANDOMIZED CONTROLLED TRIAL SPACING","volume":"80","author":"Lukas","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13075-018-1772-z","article-title":"Non-Inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis","volume":"21","author":"Gratac\u00f3s","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223298_bib48","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1001\/jama.2021.4172","article-title":"Effect of therapeutic drug monitoring vs standard therapy during infliximab induction on disease remission in patients with chronic immune-mediated inflammatory diseases: a randomized clinical trial","volume":"325","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223298_bib49","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"Syversen","year":"2021","journal-title":"JAMA"},{"key":"10.1136\/ard-2022-223298_bib50","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/annrheumdis-2020-219717","article-title":"Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)","volume":"80","author":"Landew\u00e9","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib51","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following Certolizumab pegol treatment in patients with axial spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223298_bib52","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/acr.23276","article-title":"Effects of long-term etanercept treatment on clinical outcomes and objective signs of inflammation in early Nonradiographic axial spondyloarthritis: 104-Week results from a randomized, placebo-controlled study","volume":"69","author":"Dougados","year":"2017","journal-title":"Arthritis Care Res"},{"key":"10.1136\/ard-2022-223298_bib53","first-page":"184","article-title":"Clinical experience with the European ankylosing spondylitis infliximab cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety","volume":"34","author":"Heldmann","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib54","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2017-eular.3321","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keab346","article-title":"Long-Term tolerability and efficacy of golimumab in active non-radiographic axial spondyloarthritis: results from open-label extension","volume":"61","author":"van der Heijde","year":"2022","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib56","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/rheumatology\/kex174","article-title":"Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA","volume":"56","author":"van der Heijde","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2022-223298_bib58","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.11102","article-title":"Secukinumab 150\/300 Mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis: 3-year results from the phase 3 measure 3 study","volume":"2","author":"Pavelka","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib60","doi-asserted-by":"crossref","first-page":"e001005","DOI":"10.1136\/rmdopen-2019-001005","article-title":"Long-Term efficacy and safety of secukinumab 150 Mg in ankylosing spondylitis: 5-year results from the phase III measure 1 extension study","volume":"5","author":"Baraliakos","year":"2019","journal-title":"RMD Open"},{"key":"10.1136\/ard-2022-223298_bib61","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S2665-9913(20)30066-7","article-title":"5-Year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 measure 2 trial","volume":"2","author":"Marzo-Ortega","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib62","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2021-eular.156","article-title":"POS0226\u2005BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY","volume":"80","author":"Van der Heijde","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib63","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib64","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib65","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/annrheumdis-2021-eular.2627","article-title":"POS0232\u2005CLINICAL EFFECTIVENESS OF ADALIMUMAB VERSUS NON-BIOLOGIC THERAPY IN THE MANAGEMENT OF EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS PATIENTS OVER 24 MONTHS \u2013 RESULTS OF THE COMPLETE-AS CANADIAN OBSERVATIONAL STUDY","volume":"80","author":"Bessette","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib66","doi-asserted-by":"crossref","first-page":"1132.1","DOI":"10.1136\/annrheumdis-2020-eular.4201","article-title":"SAT0370\u2005TUMOUR NECROSIS FACTOR INHIBITOR THERAPY DOES NOT REDUCE THE INCIDENCE OF COMORBIDITIES AND EXTRA-ARTICULAR MANIFESTATIONS IN ANKYLOSING SPONDYLITIS: AN ANALYSIS OF THREE US CLAIMS DATABASES","volume":"79","author":"Deodhar","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib67","first-page":"262","article-title":"Do anti-TNF agents increase the risk of inflammatory bowel disease evolution in patients with ankylosing spondylitis? real life data","volume":"111","author":"\u00dcsk\u00fcdar Cansu","year":"2019","journal-title":"J Natl Med Assoc"},{"key":"10.1136\/ard-2022-223298_bib68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/jphs.12212","article-title":"Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set","volume":"9","author":"Walsh","year":"2018","journal-title":"J Pharm Health Serv Res"},{"key":"10.1136\/ard-2022-223298_bib69","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/joim.12880","article-title":"Long-Term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial","volume":"285","author":"Goll","year":"2019","journal-title":"J Intern Med"},{"key":"10.1136\/ard-2022-223298_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20987700","article-title":"Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial","volume":"13","author":"Proft","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223298_bib71","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3899\/jrheum.180718","article-title":"Safety and efficacy of intravenous golimumab in adults with ankylosing spondylitis: results through 1 year of the GO-ALIVE study","volume":"46","author":"Reveille","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib72","doi-asserted-by":"crossref","first-page":"668","DOI":"10.14412\/1995-4484-2019-668-677","article-title":"Efficacy and safety of a new original interleukin 17A inhibitor in the treatment of patients with active ankylosing spondylitis: results of a basic (BCD-085-3\/AILAS) and extended (BCD-085-3ext\/AILAS-II) phase II clinical trial","volume":"57","author":"Erdes","year":"2019","journal-title":"Rheumatology Science and Practice"},{"key":"10.1136\/ard-2022-223298_bib73","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1080\/14397595.2021.1878985","article-title":"The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors","volume":"31","author":"Koo","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20929208","article-title":"Factors associated with sepsis risk in immune-mediated inflammatory diseases receiving tumor necrosis factor inhibitors: a nationwide study","volume":"12","author":"Chao","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223298_bib75","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/annrheumdis-2016-209270","article-title":"Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers","volume":"76","author":"Hellgren","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib76","first-page":"2665","article-title":"Malignancy risk among patients with ankylosing spondylitis in the United States: a population-based national study","volume":"72","author":"Merjanah","year":"2020","journal-title":"Arthritis and Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib77","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/annrheumdis-2015-208490","article-title":"Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish multiple sclerosis registry","volume":"75","author":"Dreyer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib79","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/annrheumdis-2022-eular.2416","article-title":"POS0939\u2005Bimekizumab in patients with active non-radiographic axial spondyloarthritis: 24-week efficacy & safety from be mobile 1, a phase 3, multicentre, randomised, placebo\u2011controlled study","volume":"81","author":"Deodhar","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/annrheumdis-2022-eular.2441","article-title":"OP0019\u2005Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy & safety from be mobile 2, a phase 3, multicentre, randomised, placebo-controlled study","volume":"81","author":"Van der Heijde","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib81","doi-asserted-by":"crossref","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"Il-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib82","doi-asserted-by":"crossref","first-page":"623874","DOI":"10.3389\/fimmu.2020.623874","article-title":"Il-23 inhibition in ankylosing spondylitis: where did it go wrong?","volume":"11","author":"Baeten","year":"2020","journal-title":"Front Immunol"},{"key":"10.1136\/ard-2022-223298_bib83","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib84","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3899\/jrheum.141335","article-title":"Is etanercept 25 Mg once Weekly as effective as 50 Mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial","volume":"42","author":"Yates","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib85","first-page":"1","article-title":"Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study","volume":"7","author":"Cantini","year":"2013","journal-title":"Biologics"},{"key":"10.1136\/ard-2022-223298_bib86","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1136\/annrheumdis-2022-222155","article-title":"EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases","volume":"82","author":"Krieckaert","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2022-223298_bib87","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211003803","article-title":"Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the multicenter phase IV C-VIEW study","volume":"13","author":"van der Horst-Bruinsma","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1136\/ard-2022-223298_bib88","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study","volume":"46","author":"van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib89","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the classic II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1136\/ard-2022-223298_bib90","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn's disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2022-223298_bib91","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1136\/ard-2022-223298_bib92","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1136\/ard-2022-223298_bib93","first-page":"592","article-title":"Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis","volume":"34","author":"Park","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib94","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/03009742.2018.1470253","article-title":"Use of disease-modifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis","volume":"48","author":"Moura","year":"2019","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard-2022-223298_bib95","first-page":"3834","article-title":"Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model","volume":"60","author":"Krabbe","year":"2021","journal-title":"Rheumatology"},{"key":"10.1136\/ard-2022-223298_bib96","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3899\/jrheum.210332","article-title":"The association of tumor necrosis factor inhibitor use with incident hypertension in ankylosing spondylitis: data from the psoas cohort","volume":"49","author":"Liew","year":"2022","journal-title":"J Rheumatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724086308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2022-223298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:03:10Z","timestamp":1779249790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724086308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0003496724086308"],"URL":"https:\/\/doi.org\/10.1136\/ard-2022-223298","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2022-223298","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}